Enzo Biochem, big biotech, enters into marketing agreement with Sequenom Laboratories for MaterniT21 PLUS
The Enzo Clinical Lab, subsidiary of big biotech, Enzo Biochem, has entered into an agreement to market early non-invasive prenatal laboratory test service, MaterniT21 PLUS, developed by the Sequenom Laboratories.
Sequenom Laboratories was the first to market a noninvasive prenatal laboratory-developed test for fetal chromosomal abnormalities.
The MaterniT21 PLUS test analyzes the relative amount of 21, 18, 13, as well as X and Y chromosomal material in cell-free DNA.
The test is intended for use in pregnant women at increased risk for fetal aneuploidy, can be used as early as 10 weeks' gestation
For further deal information visit Current Agreements (subscription required)
Read: more on Enzo Biochem company profile
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity